At 21x P/E, is Lupin an undervalued pharma giant poised for the next growth cycle?
Kort samengevat
Lupin stocks have been range-bound throughout 2025 after two years of a strong rally. Record earnings and USFDA approvals couldn’t move the stock much. Has the cyclical upside ended? Where is Lupin looking for new growth?
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij The Indian Express.
Lees het volledige bericht ↗